← FDA DRUG APPROVALS

FDA ANDA · ANDA083149

PBZ

Sponsor: NOVARTIS

APPLICATION
ANDA083149
TYPE
ANDA
ORIGINAL APPROVAL
1973-09-06
LATEST ACTION
1999-07-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

PBZDiscontinued
TRIPELENNAMINE HYDROCHLORIDE 25MG · TABLET · ORAL

Approval history

1999-07-20Manufacturing (CMC) · Supplement 20AP
1997-10-30Manufacturing (CMC) · Supplement 17AP
1997-08-06Manufacturing (CMC) · Supplement 19AP
1997-03-26Manufacturing (CMC) · Supplement 18AP
1995-08-03Manufacturing (CMC) · Supplement 16AP
1985-04-16Manufacturing (CMC) · Supplement 14AP
1985-04-16Manufacturing (CMC) · Supplement 15AP
1983-10-12Manufacturing (CMC) · Supplement 12AP
1983-10-12Manufacturing (CMC) · Supplement 10AP
1983-10-12Manufacturing (CMC) · Supplement 13AP
1973-09-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →